Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Zhang, Tao; Ma, Xinrui; Xu, Muyun; Cai, Jinghua; Cai, Jianhua; Cao, Yanguang; Zhang, Zhihao; Ji, Xin; He, Jian; Cabrera, German Oscar Fonseca; Wu, Xuedan; Zhao, Weiling; Wu, Zhanhong; Xie, Jin; Li, Zibo

doi:10.1007/s00259-024-06754-2

Eur J Nucl Med Mol Imaging

2024

DOI: 10.1007/s00259-024-06754-2

|View full text |Cite

Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Tao Zhang,

Xinrui Ma,

Muyun Xu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Previti,

Bodin,

Rémond

et al. 2024

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Previti,

Bodin,

Rémond

et al. 2024

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

Synthesis of⁶⁴Cu-,⁵⁵Co-, and⁶⁸Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles

Fonseca Cabrera,

Ma,

Lin

et al. 2024

J Nucl Med

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Cited by 2 publications

References 62 publications

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Synthesis of⁶⁴Cu-,⁵⁵Co-, and⁶⁸Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles

Contact Info

Product

Resources

About

Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Cited by 2 publications

References 62 publications

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics

Synthesis of64Cu-,55Co-, and68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles

Contact Info

Product

Resources

About

Synthesis of⁶⁴Cu-,⁵⁵Co-, and⁶⁸Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles